Needham & Company LLC restated their buy rating on shares of Immuneering (NASDAQ:IMRX - Free Report) in a research note released on Thursday morning,Benzinga reports. The brokerage currently has a $9.00 target price on the stock.
Other equities research analysts also recently issued reports about the company. Chardan Capital reiterated a "buy" rating and issued a $13.00 target price on shares of Immuneering in a report on Tuesday, May 6th. Oppenheimer lowered their target price on shares of Immuneering from $25.00 to $21.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th.
Read Our Latest Analysis on IMRX
Immuneering Trading Up 3.9%
Shares of NASDAQ:IMRX traded up $0.08 during trading on Thursday, hitting $2.13. 739,011 shares of the company's stock were exchanged, compared to its average volume of 2,338,849. Immuneering has a 1-year low of $1.00 and a 1-year high of $3.83. The firm has a 50-day moving average price of $1.42 and a two-hundred day moving average price of $1.74. The firm has a market cap of $76.65 million, a P/E ratio of -1.08 and a beta of 0.01.
Immuneering (NASDAQ:IMRX - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.41) by ($0.01). As a group, research analysts predict that Immuneering will post -1.86 EPS for the current year.
Hedge Funds Weigh In On Immuneering
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Tang Capital Management LLC acquired a new stake in Immuneering during the fourth quarter worth about $27,000. Jane Street Group LLC acquired a new position in Immuneering in the 1st quarter valued at about $32,000. Marshall Wace LLP purchased a new stake in Immuneering in the 4th quarter valued at approximately $47,000. First Manhattan CO. LLC. purchased a new position in Immuneering in the fourth quarter valued at about $71,000. Finally, XTX Topco Ltd grew its position in shares of Immuneering by 177.2% in the fourth quarter. XTX Topco Ltd now owns 32,650 shares of the company's stock valued at $72,000 after purchasing an additional 20,871 shares during the last quarter. Hedge funds and other institutional investors own 67.65% of the company's stock.
About Immuneering
(
Get Free Report)
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.
Recommended Stories
Before you consider Immuneering, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immuneering wasn't on the list.
While Immuneering currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
